Executive summary
US Patent 8,338,639 claims a soft gelatin capsule formulation for 15-keto-prostaglandin compounds, where the capsule shell uses gelatin + sugar alcohol plasticizer and the filled formulation uses a fatty acid ester or polyol pharmaceutically acceptable vehicle. Independent claim scope is broad at the vehicle level (fatty acid ester or polyol) and broad at the active level through a formula (I) covering multiple substitutions and ring unsaturation patterns, then narrows through dependent claims to specific 13,14-dihydro and 16-mono/16,16-di-halo (including 16,16-difluoro) prostaglandin E-series exemplars. Enforceability risk concentrates on whether a challenger’s product still meets the soft gelatin capsule + gelatin/sugar alcohol shell + filled vehicle (fatty acid ester or polyol) + “15-keto-prostaglandin compound of formula (I)” combination. The soft-cap differentiation is central: switching to tablets, hard capsules, microspheres, or other shell/plasticizer systems is a primary design-around vector, while swapping fatty acid esters vs polyols may preserve infringement if the claim language is met.
US Patent 8,338,639 scope and claim construction: what exactly is protected?
Core protected subject matter
US 8,338,639 protects a specific dosage form architecture and its composition parameters:
- Dosage form: a soft gelatin capsule.
- Shell composition: shell includes gelatin and a sugar alcohol as a plasticizer.
- Fill composition: capsule is filled with a mixture containing:
- a 15-keto-prostaglandin compound, and
- a pharmaceutically acceptable vehicle, where the vehicle is either:
- a fatty acid ester, or
- a polyol.
- Active claim element: the 15-keto-prostaglandin must be a compound of formula (I) with broad substituent definitions for L, M, N, A, B, R1, and Ra.
Why this matters for claim construction
The claim is an interlocking set of requirements. To infringe independent claim 1, an accused product must satisfy all of the following simultaneously:
- Soft gelatin capsule format (not just a gel-filled capsule)
- Gelatin + sugar alcohol plasticizer in the shell
- Vehicle in the fill must fall into one of the two claimed vehicle classes
- Active ingredient must fall within the formula (I) definition for “15-keto-prostaglandin compound”
Even if a product matches the active but uses a different dosage format, it can avoid claim 1.
What does “15-keto-prostaglandin compound of formula (I)” cover?
The claim’s active ingredient scope is expressed via formula (I) variables:
- L, M, N can be hydrogen, hydroxy, halogen, lower alkyl, hydroxy(lower)alkyl, lower alkanoyloxy, or oxo
- Constraint: at least one of L and M is not hydrogen
- Five-membered ring can contain at least one double bond
- A can be —CH3, or —CH2OH, —COCH2OH, —COOH, or functional derivatives
- B can be —CH2—CH2—, —CH═CH—, or —C═C—
- R1 is a saturated/unsaturated bivalent lower or medium aliphatic hydrocarbon residue, unsubstituted or substituted with halogen/lower alkyl/hydroxy/oxo/aryl/heterocycle; may have heteroatom substitution (O, N, S) on carbons
- Ra is a saturated/unsaturated lower or medium aliphatic hydrocarbon residue, unsubstituted or substituted with a long list of groups including halogen, oxo, hydroxy, lower alkyl/alkoxy, alkanoyloxy, cyclo(lower)alkyl, aryl, aryloxy, heterocyclic and heterocyclicoxy groups
This drafting tends to create broad chemical coverage for the active class, with the most specific narrowing occurring in dependent claims.
What does the shell requirement actually lock down?
Claim 1 requires:
- soft gelatin capsule shell comprising gelatin
- and sugar alcohol as a plasticizer
Dependent claim 10 narrows the sugar alcohol species (sorbitol, maltitol, hydrogenated maltose syrup, hydrogenated corn-starch derived sugar alcohol solution, and mixtures). Dependent claim 11 specifies a sorbitol/sorbitan major component.
Design-around implication: avoiding “sugar alcohol as a plasticizer” in a gelatin shell can defeat the claim even if the vehicle and active match.
Which vehicle systems are protected: fatty acid esters vs polyols in the fill?
Vehicle options in independent claim 1
- “pharmaceutically acceptable vehicle is a fatty acid ester or a polyol”
Dependent claim mapping (vehicle narrowing)
- Claim 12: vehicle is a fatty acid ester
- Claim 13: vehicle is a polyol
- Claim 14: vehicle is glycerin or propylene glycol
- Claims 20 and 21-22: reiterate sorbitol-containing shell with fatty acid ester or polyol fill
Practical reading for enforcement
- If an accused product uses a fatty acid ester vehicle in the fill, it can satisfy the vehicle element even if the exact ester differs, as long as it is a fatty acid ester.
- If it uses a polyol vehicle, the same is true for polyols; glycerin/propylene glycol are singled out in claim 14, which increases coverage for those exact choices but likely does not restrict claim 1 to them.
Design-around vector
Switching to a vehicle class outside “fatty acid ester or polyol” is the clearest avoidance path, but many formulation alternatives could still be argued as “polyol” depending on chemical definition and functionality.
How broad is the capsule limitation: is “soft gelatin capsule” the key infringement trigger?
Claim 1 is a dosage form claim. The “soft gelatin capsule shell” language is not optional.
Key elements
- Soft gelatin shell
- Shell contains gelatin + sugar alcohol plasticizer
- Filled with active + vehicle
Design-around map
- Hard capsules (no “soft gelatin capsule shell”) typically fall outside the claim.
- Tablets, suspensions, emulsions, creams, or topical forms do not meet the soft capsule limitation.
- Softgel shells without sugar alcohol plasticizer (e.g., different plasticizers or plasticizer blends) can potentially avoid the shell element.
- Even if the active and vehicle match, a dosage form change can defeat independent claim 1.
Dependent claims do not expand beyond the softgel construct, so the core limitation stays in place across the claim set provided.
Which 15-keto-prostaglandin exemplars are explicitly claimed in dependent claims?
The dependent claims list specific families and fluorinated exemplars, increasing enforcement leverage.
Dependent claim ladder
- Claim 2: 13,14-dihydro-15-keto-prostaglandin compound
- Claims 3-6: 15-keto-16-mono or 16,16-di-halogen prostaglandins; specific variants including 16,16-difluoro
- Claims 7-9: “15-keto-prostaglandin E” and specific 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1
- Claim 9: further adds 18S-methyl variant: “13,14-dihydro-15-keto-16,16-difluoro-18S-methyl-prostaglandin E1”
- Claim 15-19: reiterate the 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1 combination across sugar alcohol, vehicle, and shell variations
Claim 1 vs dependent claim specificity
- Claim 1: covers a large chemical space via formula (I), but still tied to “15-keto-prostaglandin” and specific structural variable allowances.
- Dependent claims: give clear hooks for particular members, including the E1 fluorinated series and the 18S-methyl variant.
Litigation impact: If a generic product uses one of these specifically listed actives, the patent holder can plead both independent claim 1 (if formula (I) fits) and narrower dependent claims for fallback positions.
What is the strongest legal path for enforcing US 8,338,639?
Based on the claim language you provided, enforcement leverage usually comes from proving match on the dosage form + shell plasticizer + vehicle class combination plus active identity within the chemical formula.
Most infringement-sensitive claim elements
- Soft gelatin capsule shell with sugar alcohol plasticizer
- Vehicle in the fill is fatty acid ester or polyol
- Active is a 15-keto-prostaglandin within formula (I)
- Dependent limitations for specific actives (13,14-dihydro; 16,16-difluoro; E1; 18S-methyl) and specific sugar alcohol selections (sorbitol/sorbitan)
How claim scope can be attacked
- If accused products use different plasticizers (not “sugar alcohol as a plasticizer”), they can challenge shell element satisfaction.
- If vehicles are alternative lipids or surfactants not captured as fatty acid esters or polyols, the vehicle element can be attacked.
- If the active is not within formula (I) or not a “15-keto-prostaglandin compound” as construed, active identity challenges become central.
How many distinct claim “coverage lanes” exist?
From the provided claims (1-23), there are two principal lanes:
Lane A: Independent claim structure (broad composition architecture)
- Soft gelatin capsule shell: gelatin + sugar alcohol plasticizer
- Fill vehicle: fatty acid ester or polyol
- Active: formula (I) 15-keto-prostaglandin
Lane B: Dependent tightening lanes (specific sugar alcohol, vehicle, and active members)
- Sugar alcohol selection (claim 10 and 11)
- Vehicle selection (claims 12-14)
- Active narrowing to 13,14-dihydro; 16-halo; 16,16-difluoro; E1; 18S-methyl E1 (claims 2-9; 15-19)
- A structural definition carve-out on substitution variable M (claim 23)
For litigation, Lane B is a fallback: if chemical formula coverage disputes arise, specific dependent claim members can reduce arguments about breadth.
What design-arounds are most likely to avoid the claim set provided?
Highest-probability avoidance strategies
- Avoid soft gelatin capsule (use hard capsule, tablet, liquid, or other format).
- Avoid sugar alcohol as plasticizer in the shell (use non-sugar-alcohol plasticizers in the gelatin shell).
- Avoid claimed vehicle classes in the fill:
- Use a vehicle that is neither a fatty acid ester nor a polyol (depending on what the definition of “polyol” captures under claim interpretation).
- Use an active that falls outside formula (I) or is not a 15-keto-prostaglandin as construed.
Lower-probability strategies
- Changing only one small substituent in the active may still fall within formula (I) because L, M, N and Ra/R1 definitions are broad, and double bond placement is permitted on the five-membered ring.
What is missing for an Orange Book / FDA exclusivity or Paragraph IV analysis of US 8,338,639?
No Orange Book listing, FDA application number, product name, formulation strength, dosage form code, or approval date for the specific patent is provided in the prompt. The claims alone do not permit linking to a specific reference product, listed drug, or expiration timetable. A litigation or Paragraph IV analysis also requires knowledge of:
- the NDA/ANDA/BLA,
- the listed patent’s expiration,
- and whether the patent is listed for use, manufacturing, or composition.
Because the input contains only claim text, the analysis here is confined to scope and competitive risk from claim elements rather than a full FDA/IP calendar.
Key Takeaways
- US 8,338,639 is a softgel formulation patent with a coupled structure: gelatin + sugar alcohol plasticizer in the shell, plus fill vehicle restricted to fatty acid esters or polyols.
- The active ingredient scope is broad via formula (I) but dependent claims lock in commercially relevant exemplars, including 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1 and 18S-methyl variants.
- The strongest infringement theory against a generic/competitor typically depends on proving the dosage form (soft gelatin capsule) and shell plasticizer (sugar alcohol) and vehicle class alignment, not only active identity.
- The most credible design-around is changing the dosage form/shell plasticizer system or using a non-fatty-acid-ester/non-polyol fill vehicle, rather than making incremental substitutions to the active that may still sit inside formula (I).
FAQs
1) Does US 8,338,639 cover soft gelatin capsules filled with polyols but not fatty acid esters?
Yes. Independent claim 1 includes vehicles that are either fatty acid esters or polyols, and dependent claims expressly cover polyols and specific polyols (glycerin, propylene glycol).
2) If a competitor uses the same 15-keto-prostaglandin active but a hard capsule, is it within the claim scope?
Not under claim 1 as written, because the claims require a soft gelatin capsule shell comprising gelatin and sugar alcohol plasticizer.
3) Which sugar alcohols are explicitly protected?
Claims 10 and 11 list sorbitol, maltitol, corn-starch derived hydrogenated sugar alcohol solutions, hydrogenated maltose syrup, and mixtures, with claim 11 requiring sorbitol and sorbitan as major components.
4) How much narrower is claim 2 compared with claim 1?
Claim 2 narrows the active to 13,14-dihydro-15-keto-prostaglandins, whereas claim 1 covers formula (I) 15-keto-prostaglandins more generally.
5) What dependent claims most directly target 16,16-difluoro prostaglandin E1 products?
Claims 5, 8, and 9 (and reiterated combination claims 15-19) focus on 16,16-difluoro prostaglandin E-series, specifically 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1 and 18S-methyl variants.
References (APA)
- US Patent 8,338,639. (Provided claims text in prompt).
